Area:
Neuroscience Biology, Pharmacology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Martha E. Stokely is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2007 — 2008 |
Stokely, Martha Elise |
R21Activity Code Description: To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) |
Mechanisms and Effects of Phytoestrogen Treatment in Autoimmune Optic Neuritis @ University of North Texas Hlth Sci Ctr
[unreadable] DESCRIPTION (provided by applicant): Elevated endothelin-1 (ET-1) in the optic nerve may contribute to the pathogenesis of autoimmune optic neuritis, a common early manifestation of multiple sclerosis (MS) that can be modeled in rats with myelin oligodendrocyte glycoprotein (MOG) peptide-induced autoimmune optic neuritis. Like its parent disease MS, autoimmune optic neuritis presents a coordinated but diverse set of immune, myelin, and axon pathologies affecting many cell types. Not only is ET-1 elevated in plasma and cerebral spinal fluid (CSF) of patients with MS, it is also capable of inducing most (or all) MS-associated pathologies, including aberrant fast axonal transport, under certain conditions. Answering the critical question of whether elevated ET-1 is required for the pathogenesis of these diseases has been hampered by an inability of endothelin receptor antagonists to cross the blood-brain/retinal barrier, requiring invasive methods unacceptable for routine treatment of a chronic human disorder where an orally-available treatment would be ideal. Fortunately, a recently discovered orally-available dietary substance may be useful. Trans-resveratrol is the phytoestrogen in red wine and peanuts believed responsible for the "French Paradox" through the suppression of ET-1 synthesis. Trans-resveratrol crosses the blood- brain/retinal barrier and its suppression of ET-1 synthesis in the CNS is one possible mechanism for red wine's reported ability to improve symptoms of autoimmune optic neuritis. Therefore, this application has the following specific aims: 1) To test the hypothesis that trans-resveratrol administration decreases the levels of ET-1 in optic nerve and that ET-1 levels significantly correlate with the observed MS-like pathologies in autoimmune optic neuritis. 2) To test the hypothesis that trans-resveratrol administration can reverse changes in anterograde fast axonal transport that are believed to cause axon pathologies in autoimmune optic neuritis. 3) To test the hypothesis that trans-resveratrol administration delays the development of seven different MS-associated histopathologies (affecting astrocytes, microglia, leukocytes, oligodendrocytes and neurons) during the pathogenic phase of autoimmune optic neuritis in rats. This would be predicted if trans-resveratrol inhibits CNS synthesis of ET-1 and elevation of ET-1 is a critical step for the pathogenesis of autoimmune optic neuritis. Autoimmune optic neuritis is a common early manifestation of multiple sclerosis (MS). This project evaluates whether trans-resveratrol, an orally available substance found in peanuts and red wine, can prevent, delay, and/or ameliorate the development and progression of autoimmune optic neuritis in vivo. Favorable results from this study may define a mechanism to improve clinical outcomes for MS patients. [unreadable] [unreadable] [unreadable]
|
0.969 |